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Many experimental and clinical studies 
suggest a relationship between enhanced 
angiotensin II release by the angiotensin-
converting enzyme (ACE) and the 
pathophysiology of atherosclerosis. The 
atherosclerosis-enhancing effects of 
angiotensin II are complex and 
incompletely understood. To identify anti-
atherogenic target genes, we performed 
microarray gene expression profiling of the 
aorta during atherosclerosis prevention 
with the ACE inhibitor, captopril. 
Atherosclerosis-prone apolipoprotein E 
(APOE)-deficient mice were used as a 
model to decipher susceptible genes 
regulated during atherosclerosis prevention 
with captopril. Microarray gene expression 
profiling and immunohistology revealed 
that captopril treatment for 7 months 
strongly decreased the recruitment of pro-
atherogenic immune cells into the aorta. 
Captopril-mediated inhibition of plaque-
infiltrating immune cells involved down 
regulation of the C-C chemokine receptor 9 
(CCR9). Reduced cell migration correlated 
with decreased numbers of aorta-resident 
cells expressing the CCR9-specific 
chemoattractant factor, chemokine ligand 
25 (CCL25). The CCL25-CCR9 axis was 
pro-atherogenic, because inhibition of 
CCR9 by RNA interference in 
hematopoietic progenitors of APOE-
deficient mice significantly retarded the 
development of atherosclerosis. Analysis of 
coronary artery biopsy specimens of 
patients with coronary artery 
atherosclerosis undergoing bypass surgery 
also showed strong infiltrates of CCR9-
positive cells in atherosclerotic lesions. 
Thus, the C-C chemokine receptor, CCR9, 
exerts a significant role in atherosclerosis. 
 
 Several clinical studies show that 
pharmacological inhibition of the renin-
angiotensin-aldosterone system (RAAS) could 
mediate atheroprotection (1-4). In agreement 
with those clinical data, experimental studies 
demonstrated a causal relationship between 
angiotensin II release by the angiotensin-
converting enzyme (ACE), the angiotensin II 
AT1 receptor and the development of 
atherosclerosis because genetic inactivation of 
either ACE or the AT1 receptor prevents 
atherosclerosis development in various animal 
models of atherosclerosis (5,6). Likewise, 
inhibition of angiotensin II activity by ACE 
inhibitors or AT1 receptor antagonists is 
curative in such animal models of 
atherosclerosis (7,8). 
 In view of the major anti-
atherosclerotic effects of ACE inhibitors and 
AT1 antagonists, many studies investigated 
mechanisms that could contribute to 
atheroprotection upon angiotensin II 
inhibition. The effects of angiotensin II in 
atherosclerosis are complex involving actions 
on circulating blood cells and arterial smooth 
muscle cells as major targets (9-11). 
Established pro-atherogenic effects of 
angiotensin II on smooth muscle cells are 
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related to a phenotype transformation from 
contractile to synthetic (11). The effects of 
angiotensin II on circulating immune cells are 
less clear, although, gene inactivation studies 
clearly demonstrated the involvement of 
circulating blood and progenitor cells in the 
atherosclerosis-enhancing activity of ACE and 
the AT1 receptor (9). 
 Several studies revealed that AT1 
receptor-stimulated signalling enhances the 
pro-atherogenic potential of monocytes and 
macrophages by sustaining 
monocyte/macrophage migration into the sub-
endothelial layer of the arterial wall, where 
transformation into foam cells occurs (9,10). 
In addition to macrophages, the AT1 receptor 
may also exert effects on T lymphocytes by 
supporting T lymphocyte migration into the 
perivascular tissue (12). Infiltrating T cells 
also play a role in the pathogenesis of 
atherosclerosis as demonstrated by studies 
with animal models and patients (13,14). 
However, the full impact of angiotensin II on 
peripheral immune cells in the course of 
atherosclerosis development is still not 
understood. 
 To further analyze the role of immune 
cells in the atherogenic process, and the anti-
atherogenic potential of angiotensin II 
inhibition, we performed microarray gene 
expression profiling of the aorta as the target 
organ of atherosclerosis. As a prototypic ACE 
inhibitor we chose captopril with established 
anti-atherosclerotic actions in vivo, in various 
animal models (7,10,15), and patients (16). We 
report here that inhibition of angiotensin II 
generation and atherosclerosis development by 
captopril in hypercholesterolemic APOE-
deficient mice led to a profound change of the 
aortic immune cell infiltrate, and down 
regulated the chemoattractant C-C chemokine 
receptor type 9 (CCR9), with its specific 
ligand, C-C motif chemokine 25 (CCL25). 
 
 
EXPERIMENTAL PROCEDURES 
 
 Animal experiments- For the study, 4-
6 week-old APOE-deficient mice on a 
C57BL/6J background, and non-transgenic 
C57BL/6J controls were used. Mice were kept 
on a 12 h light/12 h dark regime, had free 
access to food and water, and were fed a 
standard rodent chow containing 7 % fat and 
0.15 % cholesterol (AIN-93-based diet). As 
indicated, APOE-deficient mice received 
captopril in drinking water (20 mg/kg; 
prepared fresh every day) for 7 months, or the 
angiotensin II AT1 receptor-specific 
antagonist, losartan (30 mg/kg). At an age of 
32-34 weeks, mice were anesthetized with 
ketamine/xylazine (100/10 mg/kg), and 
perfused intracardially with sterile PBS. The 
aorta was isolated, rapidly dissected free of 
adherent adipose tissue, and immediately 
frozen in liquid nitrogen, or processed for 
further use. Total plasma cholesterol was 
determined using a standard enzymatic kit, and 
systolic blood pressure was measured by the 
tail-cuff method (10). Atherosclerotic lesion 
area of the aortic root was quantified by 
computerized image analysis as described 
(10). Mouse peripheral blood mononuclear 
cells and monocytes were isolated from 
heparin-anticoagulated blood diluted with PBS 
by density gradient centrifugation through 
Ficoll Paque or Optiprep followed by plastic 
adherence or by Nycoprep density gradients 
(10). Monocyte purity was > 80% as 
determined by immunofluorescence staining of 
cell-specific antigens (10). Monocytes were 
cultivated as described (10). All solutions and 
chemicals used in monocyte isolation and 
activation were endotoxin-free (endotoxin 
<0.008 ng/ml). 
 All animal experiments were 
performed in accordance with the NIH 
guidelines, and were reviewed and approved 
by the local committees on animal care and 
use (University of Zurich and Hamburg).  
 Patients- The study was performed 
with coronary artery biopsy specimens 
obtained form 15 patients with coronary artery 
disease undergoing coronary artery bypass 
graft surgery (diseased vessels 2.3±0.5; age 
51±6 years; 9 males). All the patients had a 
recent history of an acute coronary syndrome 
(3 weeks to 3 months prior to bypass surgery). 
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Coronary artery biopsy specimens without 
atherosclerotic lesions as confirmed by the 
absence of oil-red O-stained atherosclerotic 
lesions served as controls. Informed consent 
was obtained from all the participants. The 
study was approved by the local ethics 
committee (Ain Shams University, Cairo).  
 Bone marrow transplantation- For 
lentiviral-mediated RNA interference (RNAi) 
inhibition of CCR9 in hematopoietic 
progenitors, transduced bone marrow cells 
isolated from APOE-deficient donors (1 x 106) 
were injected into the tail vein of irradiated 11-
12 week-old, syngeneic APOE-deficient 
recipients as described previously (10). For 
RNA interference, lentiviral constructs with 
RNA polymerase II promoter-driven 
expression of micro-RNAs targeting CCR9 
(nucleotides 359-379), or β-galactosidase as a 
control (nucleotides 1298-1318) were used. 
Generation of high-titer lentiviruses and 
murine hematopoietic cell transduction were 
performed essentially as described (10,17). 
Four months after bone marrow 
transplantation, mice were sacrificed, blood 
was collected by cardiac puncture, and 
mononuclear cells were isolated for 
assessment of CCR9 protein levels (10). 
Persistent reduction of CCR9 in peripheral 
blood mononuclear cells (18) was maintained 
throughout the observation period of 4 months 
after transplantation. 
 Microarray gene expression profiling- 
Microarray gene expression analysis of the 
aorta was performed essentially as described 
previously (19). Briefly, total RNA of the 
dissected aortas was isolated with the RNeasy 
Midi kit (Qiagen). Procedures for cDNA 
synthesis, labeling and hybridization were 
carried out according to the protocol of the 
manufacturer (Affymetrix). For hybridization, 
15 µg of fragmented cRNA were incubated 
with the chip (Affymetrix GeneChip Mouse 
genome MG430 2.0 Array) in 200 µl of 
hybridization solution in a Hybridization Oven 
640 (Affymetrix) at 45 °C for 16 h. GeneChips 
were washed and stained using the Affymetrix 
Fluidics Station 450 according to the 
GeneChip Expression Analysis Technical 
Manual (Rev. 5). Microarrays were scanned 
with the Affymetrix GeneChip Scanner 7G, 
and the signals were processed with a target 
value of 200 using GCOS (v. 1.4, Affymetrix). 
All microarray gene expression data are 
available at NCBI GEO database accession no. 
GSE19286. 
 Antibodies- The following antibodies 
were used for immunohistochemistry, 
immunofluorescence, and immunoblotting: 
monoclonal rat anti-CD8a antibodies  (BD 
Pharmingen); rabbit anti-CD22 antibodies (BD 
Pharmingen); monoclonal rat anti-MOMA-2 
antibodies (Serotec); affinity-purified rabbit 
anti-AT1 receptor antibodies raised against an 
antigen corresponding to positions 306-359 of 
the mouse AT1A receptor sequence (10), 
affinity-purified rabbit/rat anti-CCR9 
antibodies raised against recombinant CCR9 
protein, or an antigen encompassing amino 
acids 321-351 of the human or mouse CCR9 
sequence, respectively; rabbit/rat anti-
mCCL25 antibodies raised against an antigen 
encompassing amino acids 1-27 of the mouse 
CCL25 sequence, or recombinant mouse 
CCL25. Recombinant CCL25 was produced in 
Escherichia coli and purified similarly as 
described (20), and the CCR9 protein was 
expressed in and purified from Spodoptera 
frugiperda cells infected with a recombinant 
baculovirus encoding CCR9 as detailed 
previously (21). Immunization of antigens (1 
mg/ml) in phosphate-buffered saline mixed 1:1 
with complete Freund`s andjuvant was done 
according to standard protocols followed by 
booster injections in incomplete Freund`s 
adjuvant 2 weeks after the first injection and 
monthly thereafter (17). Immunoblotting and 
immunohistochemistry were routinely used to 
determine and confirm cross-reactivity of the 
antibodies with the respective proteins. 
 Immunohistology and immuno-
fluorescence- For immunohistology, 
cryosections or paraffin sections of the aortic 
sinus region (10 µm, taken at 50 µm intervals 
for analyses, 10-15 sections per set) were used 
(10,17). Immunohistological detection of 
CCR9 and CCL25 was performed with 
affinity-purified, polyclonal antibodies pre-
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absorbed to mouse or human tissue similarly 
as described (10,17). All sections were imaged 
with a Leica DMI6000 microscope equipped 
with a DFC420 camera. 
 Immunofluorescence localization 
studies were performed with cryosections (10 
µm) of post-fixed and frozen aortas obtained 
from 8 month-old APOE-deficient mice. For 
co-localization of CCR9 and CCL25, affinity-
purified rabbit anti-CCL25 antibodies and rat 
anti-CCR9 antibodies were applied (dilution 
1:4000), followed by secondary antibodies or 
F(ab)2 fragments of the antibodies labelled 
with Alexa Fluor 488 and Alexa Fluor 546, 
respectively (dilution 1:5000), and 
counterstaining with DAPI. Sections were 
imaged with a Leica DMI6000 microscope and 
a Leica (TCS) confocal laser microscope. 
 Immunoblot detection of proteins- 
Immunoblot detection of proteins was 
performed as described previously with 
affinity-purified antibodies pre-absorbed to 
mouse or human proteins, respectively (10,17). 
Bound antibody was visualized with F(ab)2 
fragments of enzyme-coupled secondary 
antibodies, or by enzyme-coupled protein A 
followed by enhanced chemiluminescence 
detection. 
 Statistical Analysis- Unless otherwise 
stated, data are expressed as mean ± S.D. To 
determine significance between two groups, 
we made comparisons using the unpaired two-
tailed Student`s t test. p values of < 0.05 were 
considered significant unless otherwise 
indicated. 
 
RESULTS 
 
 Captopril inhibits atherosclerosis 
development of APOE-deficient mice. To 
assess the effect of ACE inhibition on 
atherosclerosis development, atherosclerosis-
prone, 4-6 week-old, APOE-deficient mice 
were treated for 7 months with the ACE 
inhibitor, captopril, in drinking water. After 7 
months, captopril-treated mice had a modest 
decrease in body weight and blood pressure 
relative to age-matched, non-treated APOE-
deficient mice (Fig. 1A). Those observations 
are in agreement with established effects of 
ACE and ACE inhibitors, respectively (10,22). 
In contrast, captopril, did not affect total 
plasma cholesterol levels of APOE-deficient 
mice (Fig. 1A). 
 Concomitantly, captopril treatment 
largely prevented the development of 
atherosclerotic plaques in the aortic root of 
APOE-deficient mice as evidenced by 
histological analysis (Fig. 1B; middle vs. left 
panel). As a control, the aortic root of non-
transgenic C57BL/6J mice was lesion-free 
(Fig. 1B; right panel). Quantification of the 
plaque area demonstrated that captopril 
treatment had reduced the mean aortic root 
lesion area by 79 ± 9 % relative to untreated 
APOE-deficient mice (Fig. 1C). Altogether, 
these findings confirm that captopril 
efficiently inhibits atherosclerosis 
development of APOE-deficient mice (7,10).  
 Microarray analysis of atherosclerosis 
prevention by captopril. To assess the 
mechanisms underlying atherosclerosis 
prevention mediated by captopril, we 
performed microarray gene expression 
profiling of the aorta of 8 months-old APOE-
deficient mice with overt atherosclerosis 
relative age-matched APOE-deficient mice 
treated for 7 months with the ACE inhibitor, 
captopril (Fig. 1D; middle vs. left panel). As a 
control, we used non-transgenic C57BL/6J 
mice without atherosclerosis (Fig. 1D; right 
panel). Oil-red O staining of representative 
aortas of the three study groups confirmed that 
captopril treatment for 7 months prevented the 
development of atherosclerotic plaques in the 
aorta of APOE-deficient mice whereas age-
matched APOE-deficient mice showed high 
plaque load of the aortic arch (Fig. 1D; middle 
vs. left panel). 
 For microarray analysis, total aortic 
RNA isolated of the three study groups were 
used, i.e. untreated APOE-deficient, captopril-
treated APOE-deficient, and non-transgenic 
C57BL/6J control mice. Data obtained after 
chip scanning revealed uniform quality of the 
microarrays as assessed by the comparable 
number of probe sets present, and the 
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 5 
3´/5`ratio of probe sets detecting GAPDH and 
beta actin (GEO database no. GSE19286). 
 Microarray analysis reveals 
infiltrating immune cells in the aorta of 
APOE-deficient mice. After data 
normalization, microarray data were evaluated. 
Because ACE inhibitors target inflammatory 
immune cells (9,10), we determined the impact 
of captopril on immune cell recruitment. To 
identify microarray probe sets specific of 
aorta-infiltrating immune cells, we applied a 
stringent filtering strategy (19). Aortic probe 
sets of captopril-treated APOE-deficient mice 
were selected displaying, (i) a significantly 
different signal compared to untreated APOE-
deficient mice (*, p < 0.05), (ii) a more than 50 
% reduction of signal intensity relative to 
untreated APOE-deficient mice, (iii) 
membrane localization according to gene 
ontology (GO) analysis, and (iv) immune cell 
specificity. The very stringent approach 
identified only 9 differentially expressed probe 
sets, which showed effects of captopril on the 
infiltration of the aorta with immune cells (Fig. 
2A). Notably, captopril normalized the 
increased aortic expression of T cell- and 
macrophage-specific marker proteins of 
APOE-deficient mice, i.e. CD8a, CD8b, CD4, 
CD28, CCR9, and Mmd (monocyte to 
macrophage differentiation-associated) (Fig. 
2A). In contrast, B lymphocyte-specific 
markers, such as CD79a and CD22, were not 
significantly affected by captopril (Fig. 2A). 
As a control, atherosclerosis development of 
APOE-deficient mice was accompanied by a 
strong up-regulation of all mononuclear cell-
specific probe sets relative to non-transgenic 
C57BL/6J controls, i.e. T cell-, macrophage- 
and B cell-specific marker proteins (Fig. 2A). 
Thus, the microarray approach was capable to 
detect aorta-infiltrating immune cells in the 
course of atherosclerosis development. 
 Captopril suppresses aortic T cell 
infiltration of APOE-deficient mice. To 
validate the microarray data regarding the 
observed effect of captopril on aortic T cell 
recruitment, we performed immunohistology 
analysis of the aortic sinus region. 
Immunostaining with antibodies specifically 
recognizing CD8a revealed that captopril 
significantly suppressed the infiltration of the 
aortic sinus region with CD8a-positive cells 
(Fig. 2B, middle vs. left panel). As a control, 
non-transgenic C57BL/6J control mice did not 
show substantial infiltration of the aorta with 
CD8a-positive cells compared to APOE-
deficient mice (Fig. 2B, right vs. left panel). 
 The CD8a positive cells did not stain 
positive for the dendritic cell-specific marker 
protein, CD11c (data not shown). In addition, 
the microarray data did not show a significant 
difference in the expression of CD11c between 
untreated and captopril-treated APOE-
deficient mice (cf. GSE19286). 
 Altogether, the data are compatible 
with the notion that captopril suppresses aortic 
T cell infiltration of APOE-deficient mice. 
Since T cells are considered pro-atherogenic 
(13), suppression of T cell migration may 
contribute to atherosclerosis prevention 
exerted by captopril. 
 Captopril maintains the presence of B 
lymphocytes in the aorta of atherosclerosis-
prone APOE-deficient mice. We also used 
immunohistology to validate the microarray 
data on B cell migration. In contrast to T cells, 
B lymphocytes are considered atheroprotective 
(23). In agreement with the microarray data, 
captopril treatment did not significantly reduce 
the presence of B cells in the aorta of APOE-
deficient mice according to immunohistology 
analysis applying CD22-specific antibodies 
(Fig. 2C, middle vs. left panel). As a control, B 
cells were largely absent in non-transgenic 
C57BL/6J control mice (Fig. 2C, right vs. left 
panel). Altogether, captopril treatment may 
sustain the migration of atheroprotective B 
cells into the aorta of atherosclerosis-prone 
APOE-deficient mice while suppressing the 
aortic infiltration with atherosclerosis-
promoting T cells. 
 Captopril suppresses the recruitment 
of CCR9-positive immune cells into the aorta 
of APOE-deficient mice. In addition to the 
lymphocyte markers for T cells and B cells, 
the microarray data revealed the strong up-
regulation of three different probe sets 
detecting CCR9 in the atherosclerotic aorta of 
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APOE-deficient mice relative to non-
transgenic controls (Figs. 2A and 3A). All 
three probe sets were substantially down 
regulated by captopril treatment (Fig. 3A). 
Immunoblotting with CCR9-specific 
antibodies (Fig. 3B, lane 1 vs. 2) confirmed the 
microarray data revealing a strong reduction of 
aortic CCR9 protein levels upon captopril 
treatment (Fig. 3B; lane 4 vs. 3; and cf. Fig. 
8D). As a control, non-transgenic control mice 
did not show significant CCR9 protein levels 
in the aorta (Fig. 3B, lane 5). 
 CCR9 is expressed on various immune 
cells including T cells and macrophages 
(20,24). Immunohistology was performed to 
identify the aorta-infiltrating cells, which were 
CCR9-positive. Immunohistology of aortic 
sinus sections with CCR9-specific antibodies 
showed localization of CCR9 on plaque-
resident cells of the atherosclerotic aorta (Fig. 
3C, left panel). CCR9-positive cells were 
strongly reduced by captopril treatment and 
virtually absent in non-transgenic C57BL/6J 
controls (Fig. 3C, middle and right panel). 
 Some CCR9-positive cells were 
docking to the atherosclerotic intima from the 
side of the aortic lumen suggesting that CCR9-
positive cells could be derived from circulating 
immune cells (Fig. 3D; cf. Fig. 4). As a 
control, significant staining of endothelial cells 
by CCR9-specific antibodies was not observed 
(data not shown). 
 Immunofluorescence was applied to 
determine the cellular localization of CCR9. 
Membrane-localized CCR9 was present on 
cells, which displayed characteristics of 
macrophages differentiating into foam cells 
with multiple cell nuclei (Fig. 3E). CCR9-
positive cells in the atherosclerotic aortic 
intima of APOE-deficient mice were localized 
in close proximity to cells releasing the CCR9-
specific chemoattractant, CCL25 (Fig. 3E). 
Thus, atherosclerotic plaques of APOE-
deficient mice show CCR9-positive cells, and 
captopril treatment strongly reduced the 
recruitment of aorta-infiltrating CCR9-positive 
cells. 
 CCR9 localization on plaque-resident 
macrophages and circulating monocytes. We 
next asked whether the plaque-resident CCR9-
positive cells showed characteristics of 
macrophages as a major source of foam cells. 
Immunofluorescence studies revealed the co-
localization of CCR9 with the 
monocyte/macrophage-specific marker, 
MOMA-2, on plaque-resident 
macrophages/foam cells of the aorta (Fig. 4A). 
In agreement with the migration of blood-
derived monocytes into the inflamed aortic 
intima, circulating MOMA-2-positive 
monocytes of APOE-deficient mice also 
stained positive for the CCR9 protein (Fig. 
4B). In contrast, circulating mononuclear cells 
of captopril-treated and non-transgenic control 
mice did not show significant CCR9 protein 
levels (cf. Figs. 6A, 7C). In addition to 
monocytes and macrophages, plaque-
infiltrating and circulating CD8a+ T cells were 
also CCR9-positive (Fig. 4C, D).  
 Captopril reduces plaque-resident 
CCL25-positive cells. The C-C chemokine, 
CCL25, attracts CCR9-positive cells (20, 24). 
Immunohistology revealed the CCR9-specific 
chemoattractant, CCL25, in the atherosclerotic 
aortic root with advanced plaques adjacent to 
necrotic core areas (Fig. 5A). In agreement 
with the immunohistology data, there was a 
significantly increased CCL25 expression in 
the atherosclerotic aorta relative to non-
transgenic C57BL/6J control mice (Fig. 5B). 
Interestingly, atherosclerosis prevention by 
captopril treatment largely suppressed the 
increase in aortic CCL25 expression of APOE-
deficient mice (Fig. 5B). The microarray data 
on CCL25 expression in the atherosclerotic 
aorta were confirmed by immunoblotting with 
CCL25-specific antibodies (Fig. 5C). 
  Immunohistology revealed the CCL25 
protein on plaque-infiltrating cells of the 
atherosclerotic aortic intima of APOE-
deficient mice (Fig. 5D, left panel). Infiltration 
of the aortic intima with CCL25 positive cells 
was strongly reduced by captopril treatment 
(Fig. 5D, middle panel). As a control, the 
aortic intima of non-transgenic C57BL/6J 
control mice did not show significant numbers 
of CCL25 positive cells (Fig. 5D, right panel). 
Thus, atherosclerosis development is 
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accompanied by the appearance of CCL25 and 
its specific receptor, CCR9, on plaque-
infiltrating cells of APOE-deficient mice. On 
the other hand, prevention of atherosclerosis 
development by captopril down-regulated the 
CCL25-CCR9 axis. 
 CCL25 co-localizes with the 
angiotensin II AT1 receptor on plaque-resident 
cells. Enhanced activation of AT1 receptors by 
ACE-dependent angiotensin II generation is 
considered to be causally involved in 
atherogenesis (5-8,10). To assess whether 
there could be a relationship between the AT1 
receptor and plaque-infiltrating CCL25 
positive cells, we performed 
immunofluorescence localization of AT1 and 
CCL25. Immunofluorescence data with AT1-
specific and CCL25-specific antibodies, 
respectively, showed localization of the AT1 
receptor on plaque-infiltrating CCL25-positve 
cells of APOE-deficient mice (Fig. 5E). This 
finding strongly suggests that AT1-stimulated 
signalling could directly modulate the 
expression of CCL25. Previous findings 
support such a conclusion demonstrating that 
AT1-mediated signalling triggers the 
expression of Egr-1 (early growth response  
protein 1) target genes such as CCL25 (25,26). 
 In agreement with that notion, 
treatment of APOE-deficient mice with the 
AT1-specific antagonist losartan reduced the 
aortic protein levels of CCL25 by 89±6 % 
similarly as did the ACE inhibitor captopril 
(n=3 mice/group, *, p<0.0004; Fig. 5F). 
Together these data suggest a causal 
relationship between enhanced AT1 receptor 
activation and plaque-infiltrating CCL25-
positive cells. 
 Inhibition of ACE-dependent 
angiotensin II AT1 receptor activation reduces 
CCR9 protein levels of circulating 
mononuclear cells. We next analyzed the 
relationship between the AT1 receptor and the 
CCL25-specific receptor, CCR9. The CCR9 
protein is expressed on plaque-infiltrating cells 
and on circulating mononuclear cells of 
APOE-deficient mice (cf. Fig. 4). Treatment 
with the ACE inhibitor captopril strongly 
decreased mononuclear cell CCR9 protein 
levels of APOE-deficient mice by 84±6 % 
(n=4 mice/group, *, p<0.001; Fig. 6A). In 
addition, treatment of APOE-deficient mice 
for 7 months with the angiotensin II AT1 
receptor-specific antagonist, losartan, similarly 
reduced the CCR9 protein by 81±6 % (n=4 
mice/group; *, p<0.001; Fig. 6A). Together 
these observations indicate, that 
atherosclerosis development of APOE-
deficient mice is accompanied by an AT1 
receptor-dependent up-regulation of the CCR9 
protein on circulating mononuclear cells. 
 AT1 receptor activation increases 
CCR9 protein levels of cultivated monocytes. 
The causal relationship between increased 
CCR9 protein levels and AT1 receptor 
activation was analyzed with cultivated 
monocytes isolated from APOE-deficient 
mice. Incubation of cultivated monocytes for 
48 h with the AT1 receptor antagonist, 
losartan, significantly reduced the angiotensin 
II-stimulated increase in CCR9 protein levels 
by 61± 7 % (n=3, *, p<0.01) as determined by 
immunoblotting (Fig. 6B). As a control, 
losartan had no significant effect on cultivated 
monocytes in the absence of angiotensin II 
(Fig. 6B). Thus, AT1 receptor activation 
increases CCR9 protein levels of cultivated 
monocytes isolated from APOE-deficient 
mice. 
 Co-localization of AT1 and CCR9 on 
plaque-resident cells. In addition to circulating 
monocytes, CCR9 is present on plaque-
resident macrophages (cf. Fig. 4A,B). 
Immunofluorescence co-localization studies 
with CCR9-specific and AT1-specific 
antibodies, respectively, revealed localization 
of AT1 on CCR9-positive plaque-resident cells 
of APOE-deficient mice (Fig. 6C). Together 
these findings strongly suggest the 
involvement of enhanced AT1-stimulated 
signalling in the increased CCR9 protein levels 
of circulating monocytes and plaque-resident 
macrophages/foam cells of APOE-deficient 
mice. 
 Inhibition of CCR9 in hematopoietic 
progenitors retards atherosclerosis 
development of APOE-deficient mice. To 
analyze whether recruitment of CCR9-positive 
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immune cells into the aorta of APOE-deficient 
mice was involved in atherosclerosis 
development, we down-regulated the 
expression of CCR9 in vivo by bone marrow 
transplantation of syngeneic (APOE-deficient) 
hematopoietic progenitors transduced with a 
lentivirus targeting CCR9 by RNA 
interference (RNAi). The CCR9-RNAi 
lentivirus specifically reduced the protein 
expression of CCR9 without significantly 
affecting other related receptors, e.g. CCR6 
and CCR7, as assessed with lentivirus-
transduced receptor-expressing NIH3T3 cells 
(Fig. 7A). Four months after bone marrow 
transplantation, APOE-deficient mice with 
lentivirus-mediated RNAi inhibition of CCR9 
showed a significant reduction of circulating 
mononuclear cell CCR9 protein levels relative 
to control APOE-deficient mice receiving 
bone marrow transduced with a control 
lentivirus (Fig. 7B). RNAi-mediated inhibition 
of CCR9 induced a decrease of CCR9 protein 
levels on circulating mononuclear cells by 
89±6 % (n=5 mice/group, *, p<0.001) as 
determined by densitometric immunoblot 
scanning (Fig. 7B). 
 The RNAi-mediated down regulation 
of CCR9 in APOE-deficient mice was 
comparable to the captopril-induced inhibition 
of CCR9 protein levels (Fig. 7C). The 
induction of the CCR9 protein on circulating 
mononuclear cells was related to 
atherosclerosis development, because 
mononuclear cells of non-transgenic 
C57BL/6J control mice did not show 
significant CCR9 protein levels (Fig. 7C). 
 Immunofluorescence studies showed 
that plaque-resident cells were positive for 
CCR9 and the T cell- and 
monocyte/macrophage-specific immune cell 
markers, CD8a and MOMA-2 (cf. Fig. 4). 
Lentiviral-mediated RNAi inhibition of CCR9 
in hematopoietic progenitors and circulating 
immune cells (cf. Fig. 7B) was accompanied 
by a significant reduction of aortic CCR9 
protein levels of APOE-deficient mice by 
67±8% (n=5, *, p<0.001; Fig. 7D). As a 
control, treatment with captopril and losartan 
led to a comparable decrease of the aortic 
CCR9 protein of APOE-deficient mice (Fig. 
7D). 
 Next we assessed atherosclerosis 
progression upon inhibition of CCR9 
expression. Quantification of the 
atherosclerotic lesion area of the aorta revealed 
that inhibition of CCR9 by RNAi significantly 
reduced the development of the atherosclerotic 
lesion area by 55 ± 13 % (n=5 mice/group, *, 
p<0.001; Fig. 7E and F). As a control, down 
regulation of CCR9 did not significantly affect 
plasma cholesterol, body weight or blood 
pressure (Fig. 7G). Together these findings 
strongly indicate that the CCR9-CCL25 axis 
contributes to the development of 
atherosclerosis of APOE-deficient mice. 
 Infiltrates of CCR9-positive cells in 
atherosclerotic lesions of patients with 
coronary artery disease. To analyze the 
potential impact of CCR9 for atherosclerosis 
development in patients, we determined the 
CCR9 protein in atherosclerotic lesions of 
patients with coronary artery atherosclerosis 
undergoing coronary artery bypass surgery. 
Coronary artery biopsy specimens with 
atherosclerotic lesions as determined by 
positive oil-red O staining showed a strong 
infiltration of CCR9-positive cells (Fig. 8A, B; 
left panels). For comparison, coronary artery 
biopsy specimens without atherosclerotic 
lesions as verified by the absence of oil-red O-
positive lesions, did not show significant 
CCR9 staining (Fig. 8A, B; right panels). 
 Immunoblot detection with CCR9-
specific antibodies confirmed the CCR9 
protein on atherosclerotic lesions of patients 
(Fig. 8C). For comparison, vessel biopsy 
specimens without atherosclerotic lesions did 
not show significant CCR9 protein levels (Fig. 
8C). As a control, the CCR9 antibodies cross-
reacted specifically with the human CCR9 
protein of transfected HEK cells whereas the 
antibodies did not interact with mock-
transfected control cells (Fig. 8C, lane 1 versus 
2). Altogether, atherosclerotic lesions of 
patients and mice showed a strong infiltration 
with CCR9-positive cells. 
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DISCUSSION 
 
 Inflammation plays an important role 
in the pathogenesis of atherosclerosis because 
atherosclerotic plaque development involves 
the migration of pro-inflammatory immune 
cells into the arterial wall. Several studies with 
animal models of atherosclerosis showed that 
C-C chemokine receptors are important for the 
initiation and progression of atherosclerotic 
plaque formation by recruiting 
monocytes/macrophages into the sub-
endothelial layer (27). Evidence for the causal 
involvement of individual C-C chemokines 
and their receptors is provided by gene 
inactivation and over-expression studies in 
mice (28-30). In addition to the experimental 
data, clinical studies with patients confirmed 
the up-regulation of several C-C chemokines 
in patients with atherosclerosis, unstable 
angina pectoris and myocardial infarction 
(31,32). The important role of C-C 
chemokines in atherogenesis was further 
confirmed by broad-spectrum C-C chemokine 
blockers, which inhibited atherosclerotic 
plaque formation in mice (33,34). The latter 
studies point to the therapeutic potential of C-
C chemokine receptor blockade for 
atherosclerosis. 
 The present study investigated the 
impact of pro-inflammatory immune cells for 
atherosclerosis development by microarray 
gene expression analysis of aortic genes from 
atherosclerotic APOE-deficient mice relative 
to ACE inhibitor-treated mice. Microarray 
analysis and immunohistology revealed 
substantial effects of ACE inhibitor therapy on 
immune cell recruitment into the aorta. The 
study identified the strong up-regulation of a 
C-C chemokine receptor axis in atherosclerotic 
lesions, i.e. atherosclerosis development was 
accompanied by a strong increase of plaque-
resident immune cells, which were positive for 
the chemoattractant CCL25, and its receptor 
CCR9. Atherosclerosis treatment by captopril 
reduced the aortic infiltration with CCR9- and 
CCL25-positive immune cells. That 
observation is intriguing because there seems 
to be a causal relationship between 
atherosclerosis-induced angiotensin II-AT1 
receptor activation and enhanced CCR9-
CCL25 expression: The expression of CCL25 
as an Egr-1 target gene (25), could be directly 
triggered by angiotensin II-mediated AT1 
receptor signalling, which induces Egr-1 
activation (26). In agreement with that notion, 
the AT1 receptor protein was co-localized with 
CCR25 on plaque-resident cells of APOE-
deficient mice. Moreover, treatment with the 
AT1-specific antagonist, losartan, reduced the 
number of plaque-resident CCL25-positive 
cells in vivo. 
 Analogously to CCL25, the up-
regulation of CCR9 in the course of 
atherosclerosis could be also mediated by 
angiotensin II-dependent AT1 receptor 
activation because ACE inhibition and AT1 
antagonism blunted the increased mononuclear 
cell CCR9 protein levels of APOE-deficient 
mice, and the aortic recruitment of CCR9-
positive immune cells. Moreover, angiotensin 
II-dependent AT1 receptor activation directly 
stimulated an increase in CCR9 protein levels 
of isolated monocytes. Moreover, the AT1 
receptor protein was expressed on CCR9-
positive cells of atherosclerotic plaques. A 
causal relationship between CCR9 expression 
and AT1 receptor activation is also suggested 
by previous data, and could involve the AT1-
dependent induction of tumour necrosis factor 
alpha (TNF-alpha) synthesis (35,36). 
 In addition to the relationship between 
the angiotensin II system and CCR9-CCL25 
protein expression, several lines of evidence 
support the concept of a causal involvement of 
the CCR9-CCL25 axis in atherosclerosis 
development. (I) Immunohistology and 
immunofluorescence data revealed circulating 
CCR9-positive monocytes and plaque-resident 
CCR9-positive macrophages with 
characteristics of multinucleated, plaque-
forming foam cells in APOE-deficient mice. 
(II) CCR9-positive monocytes/macrophages 
are attracted by CCL25, which was released 
into the plaque-forming aortic intima from 
aorta-resident cells. (III) Inhibition of CCR9 
by RNA interference significantly attenuated 
the formation of atherosclerotic plaques of 
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APOE-deficient mice. (IV) Atherosclerotic 
lesions of patients with coronary artery 
atherosclerosis showed a strong infiltration of 
CCR9-positive cells. Thus, the study identified 
the pro-atherogenic role of the C-C 
chemoattractant receptor, CCR9 and its 
specific ligand, CCL25.  
 In agreement with an atherosclerosis-
enhancing function, the CCR9/CCL25 axis is 
induced by several pro-inflammatory and pro-
atherogenic stimuli such as interferon-gamma, 
macrophage-colony stimulating factor (M-
CSF), and TNF-alpha (37-39). Those 
CCR9/CCL25-inducing factors are causally 
involved in atherosclerosis development 
(40,41). Therefore targeting of the CCL25-
CCR9 axis may have potential significance in 
diagnosing and treating atherosclerotic plaque 
formation independently of the angiotensin II 
system. 
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FIGURE LEGENDS 
 
 Fig. 1. Captopril inhibits atherosclerosis development of APOE-deficient mice. A. 
Characteristic parameters of the three study groups, i.e. untreated APOE-deficient (APOE-/-), 
captopril-treated APOE-deficient (+Captopril, APOE-/-) and non-transgenic C57BL/6J control 
(Control) mice (age 32-34 weeks). Data represent mean ± S.D., n=5 mice/group; *, p<0.01 (APOE-/- 
vs. Captopril); §, p<0.05 (APOE-/- vs. Captopril);  †, p<0.05 (APOE-/- vs. Control); #, p<0.05 (Captopril 
vs. Control); analysis of variance with Dunn`s multiple comparison test. B. Representative 
hematoxylin-eosin (H&E) stained sections representing the mean aortic root lesion area of 32-34 
week-old APOE-deficient (APOE-/-; left panel), captopril-treated APOE-deficient (+Capto., APOE-/-; 
middle panel) and non-transgenic C57BL/6J control (Control; right panel) mice demonstrate that 
captopril suppressed atherosclerotic plaque formation of APOE-deficient mice (bar: 500 µm). C. 
Quantification of atherosclerotic lesion area in the aortic root of 32-34 week-old untreated APOE-
deficient (APOE-/-) and captopril-treated APOE-deficient (+Capto., APOE-/-) mice; n=5 mice/group; 
***, p<0.0001. D. Representative oil-red O-staining of atherosclerotic plaques in the aortic arch of an 
untreated APOE-deficient mouse (APOE-/-; left panel) relative to captopril-treated APOE-deficient 
(+Captopril, APOE-/-; middle panel) and non-transgenic C57BL/6J control (Control; right panel) mice.  
 
 Fig. 2. Microarray analysis reveals infiltrating immune cells in the aorta of APOE-deficient 
mice. A. Normalized signal intensity values of differentially expressed probe sets detecting immune 
cell-specific markers in the aortas of captopril-treated APOE-deficient (+Captopril, APOE-/-) relative 
to untreated APOE-deficient (APOE-/-) mice are presented as heat map centered to the median value. 
Probe sets of captopril-treated mice, which showed (i) a significantly different signal intensity value 
relative to untreated APOE-deficient mice (p<0.05), (ii) a more than 50 % reduction of signal 
intensity relative to untreated APOE-deficient mice, (iii) membrane localization, and (iv) immune cell 
specificity are listed. As a control, the B cell-specific probe sets of Cd79a and Cd22 were also 
included, which are not different between captopril-treated and untreated APOE-deficient mice. For 
comparison, all immune cell markers were significantly different between non-transgenic C57BL/6J 
control mice (Control) and APOE-deficient mice (p<0.05). B. Immunohistology analysis of 
infiltrating T cells in aortic root sections of an APOE-deficient (APOE-/-; left panel), captopril-treated 
APOE-deficient (+Captopril, APOE-/-; middle panel), and non-transgenic C57BL/6J control (Control; 
right panel) mouse was performed with anti-CD8a antibodies. C. Detection of infiltrating B cells by 
immunohistology of aortic root sections of an APOE-deficient (APOE-/-; left panel), captopril-treated 
APOE-deficient (+Captopril, APOE-/-; middle panel), and non-transgenic C57BL/6J control (Control; 
right panel) mouse was performed with CD22-specific (anti-CD22) antibodies (bar: 20 µm). 
Immunohistology data are representative of at least 3 different mice per group (B, C). 
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 Fig. 3. Captopril suppresses the recruitment of CCR9-positive immune cells into the aorta of 
APOE-deficient mice. A. Microarray data show down-regulation of aortic CCR9 expression of 
captopril-treated APOE-deficient mice (+Captopril, APOE-/-) relative to untreated APOE-deficient 
mice (APOE-/-). For comparison, the decreased signal intensities of the CCR9-specific probe sets of 
non-transgenic C57BL/6J control mice (Control; APOE+/+) are also presented. Relative expression 
values of the CCR9-specific probe sets are presented as % of APOE-/-, i.e. 100 % (*, p<0.04). B. 
Immunoblot detection of the CCR9 protein (IB: anti-CCR9) was performed with affinity-purified 
CCR9-specific antibodies on HEK cell membranes, transfected with (+) and without (-) a plasmid 
encoding CCR9 (lanes 1,2), and on aortic membranes isolated from an untreated APOE-deficient 
(APOE-/-, Untreat., lane 3), a captopril-treated APOE-deficient (APOE-/-, Capto., lane 4) and a non-
transgenic C57BL/6J control (APOE+/+, Cont., lane 5) mouse, respectively. Immunoblot data are 
representative of 4 different mice/group. Lane P is a specificity control showing an immunoblot of 
aortic membranes from an APOE-deficient mouse and pre-absorption of the antibodies with the 
antigen used for immunization. The lower panel shows an immunoblot of β-actin demonstrating equal 
protein loading. C. Immunohistology detection of CCR9 with affinity-purified CCR9-specific 
antibodies on aortic root sections of APOE-deficient (APOE-/-; left panel), captopril-treated APOE-
deficient (+Captopril, APOE-/-; middle panel) and non-transgenic C57BL/6J control (Control; right 
panel) mice (bar: 100 µm). D. Immunohistology detection of CCR9-positive cells (marked by arrows) 
docking to the aortic intima (with atherosclerotic plaque, Pl) from the side of the aortic lumen (Lu) of 
an APOE-deficient mouse (APOE-/-). The aortic root section was counterstained with hematoxylin 
(bar: 20 µm). E. CCR9-positive cells in the aortic root section (with atherosclerotic plaque, Pl) of an 
APOE-deficient mouse (APOE-/-) were detected by immunofluorescence with affinity-purified, rat 
anti-CCR9 antibodies followed by F(ab)2 fragments of Alexa Fluor 546-labeled secondary antibodies 
(red). The presence of CCL25 was detected with affinity-purified, rabbit anti-CCL25 followed by 
F(ab)2 fragments of Alexa Fluor 488-labeled secondary antibodies (green). Cell nuclei were stained 
with DAPI (blue). Arrows point to multinucleated CCR9-positive foam cells. Autofluorescence marks 
internal elastic lamina (bar: 20 µm). Immunohistology/immunofluorescence data are representative of 
at least 3 different mice/group (C-E). 
 
 Fig. 4. CCR9 localization on plaque-resident macrophages and circulating monocytes. A. 
Localization of CCR9 on MOMA-2-positive macrophages/foam cells of the aortic root of an APOE-
deficient mouse (APOE-/-). Aortic lumen (Lu) and plaque area (Pl) are indicated on the phase contrast 
image (right upper panel; overlay CCR9/MOMA-2). B. Circulating MOMA-2-positive monocytes of 
APOE-deficient mice are also CCR9-positive. C. The CCR9 protein is localized on CD8a positive 
cells of the aortic root of APOE-deficient mice. Aortic lumen (Lu) and plaque area (Pl) are indicated 
on the phase contrast image (right upper panel; overlay CCR9/CD8a/DAPI). D. Circulating CD8a-
positive cells are CCR9-positive. CCR9-positive cells were detected by immunofluorescence on aortic 
cryosections (A,C) or on circulating cells (B,D) with affinity-purified, rabbit anti-CCR9 antibodies 
(anti-CCR9) followed by F(ab)2 fragments of Alexa Fluor 488-labeled secondary antibodies (green, 
A-D). The presence of the monocyte-macrophage-specific marker, MOMA-2, was detected with rat 
anti-MOMA-2 antibodies (anti-MOMA) followed by F(ab)2 fragments of Alexa Fluor 546-labeled 
secondary antibodies (red, A,B). CD8a-positive cells were identified by rat anti-CD8a antibodies (anti-
CD8a) followed by F(ab)2 fragments of Alexa Fluor 546-labeled secondary antibodies (red, C,D). Cell 
nuclei were stained with DAPI (blue, A-D; bar: 20 µm). Immunofluorescence data are representative 
of at least 3 different mice. 
 
 Fig. 5. Captopril reduces plaque-resident CCL25-positive cells. A. Immunohistology detection 
of CCL25 on an aortic root section of an APOE-deficient mouse (APOE-/-) was performed with 
affinity-purified anti-CCL25 antibodies (anti-CCL25) visualizing CCL25 adjacent to a necrotic 
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centre. Cell nuclei were stained with hematoxylin (HE; bar: 20 µm). B. Microarray data reveal down 
regulation of aortic CCL25 expression by captopril treatment (+Captopril, APOE-/-) relative to 
untreated APOE-deficient (APOE-/-) mice. For comparison, the relative signal intensity of the CCL25-
specific probe set of non-transgenic C57BL/6J control mice (Control; APOE+/+) is also presented. The 
relative expression values of the probe set are presented as % of APOE-/-, i.e. 100 % (*, p≤0.01). C. 
Immunoblot detection of CCL25 with affinity-purified CCL25-specific antibodies (IB: anti-CCL25) 
in aortic tissue isolated from an untreated APOE-deficient mouse (-/-; -), a captopril-treated APOE-
deficient mouse (-/-; +Capto.), or an untreated non-transgenic C57BL/6J control mouse (+/+; -). Lane 
P is a specificity control showing an immunoblot of aortic tissue from APOE-deficient mice and pre-
absorption of the antibodies with the antigen used for immunization. The lower panel shows an 
immunoblot of β-actin demonstrating equal protein loading. The immunoblots are representative of 4 
different mice/group. D. Immunohistology detection of CCL25 with affinity-purified CCL25-specific 
antibodies (anti-CCL25) on aortic root sections of APOE-deficient (APOE-/-; left panel), captopril-
treated APOE-deficient (+Captopril, APOE-/-; middle panel) and non-transgenic C57BL/6J control 
mice (Control; right panel). Lumen (Lu) and plaque (Pl) area are indicated, bar: 20 µm. E. 
Immunofluorescence detection of CCL25 on plaque-resident cells of an APOE-deficient mouse. 
CCL25 was detected with affinity-purified, rat anti-CCL25 antibodies followed by F(ab)2 fragments 
of Alexa Fluor 488-labeled (green) secondary antibodies (left/right panels). The CCL25-positive cells 
co-localized with AT1, which was detected with affinity-purified, rabbit anti-AT1 antibodies followed 
by F(ab)2 fragments of Alexa Fluor 546-labeled (red) secondary antibodies (left/middle panels). Cell 
nuclei were stained with DAPI (blue, left panel) (bar: 20 µm). Immunohistology/immunofluorescence 
data are representative of at least 3 different mice/group (A,D,E). F. Immunoblot detection of CCL25 
with affinity-purified CCL25-specific antibodies (IB: anti-CCL25) in aortic tissue isolated from 
losartan-treated (Losartan), untreated (Untreated) and captopril-treated (Captopril) APOE-deficient 
mice (n=3 mice/group). The lower panel is a control immunoblot detecting β-actin (IB: anti-actin). 
The right panel shows quantification of relative CCL25 protein levels by densitometric immunoblot 
scanning (Untreated; 100 %). Data represent mean ± S.D., n=3 mice/group; *, p<0.0004.  
 
 Fig. 6. Inhibition of ACE-dependent angiotensin II AT1 receptor activation reduces CCR9 
protein levels of circulating mononuclear cells. A. Immunoblot detection of CCR9 (IB: anti-CCR9) on 
mononuclear cell membranes (Mononucl. cells) isolated from 32 week-old untreated APOE-deficient 
mice (-), captopril-treated (Capto.), and losartan-treated (Losart.) APOE-deficient mice (n=4 
mice/group). The lower panel is a control immunoblot of β-actin (IB: anti-actin) demonstrating equal 
protein loading (IB: anti-actin). The right panel shows quantification of the relative CCR9 protein 
levels by densitometric immunoblot scanning (Untreated,-; 100 %). Data represent mean ± S.D., n=4 
mice/group; *, p<0.001. B. Immunoblot detection of CCR9 (IB: anti-CCR9) on cultivated monocytes 
(cultiv.) isolated from APOE-deficient mice. Cultivated monocytes were incubated for 30 h in the 
absence (-) or presence (+) of angiotensin II (Ang; 50 nM), and/or losartan (Losart.; 5 µM; added 30 
min before angiotensin II) as indicated. The left panel shows a representative immunoblot, and the 
right panel shows quantification of the relative CCR9 protein levels by densitometric immunoblot 
scanning of three independent experiments (Ang,+; 100 %). Data represent mean ± S.D., n=3; *, 
p<0.01. C. Immunofluorescence reveals co-localization of CCR9 and AT1 on plaque-resident cells of 
APOE-deficient mice. CCR9 was detected with affinity-purified, rat anti-CCR9 (anti-CCR9) 
antibodies followed by F(ab)2 fragments of Alexa Fluor 488-labeled (green) secondary antibodies. 
Detection of the AT1 receptor was performed with affinity-purified anti-AT1 antibodies from rabbit 
(anti-AT1) followed by Alexa Fluor 546-labeled (red) secondary antibodies. Cell nuclei were stained 
with DAPI (blue). Lumen (Lu) and plaque (Pl) area are indicated on the phase contrast image (overlay 
CCR9/AT1/DAPI), bar: 20 µm. Immunofluorescence data are representative of 3 different mice. 
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 Fig. 7. Inhibition of CCR9 in hematopoietic progenitors retards atherosclerosis development 
of APOE-deficient mice. A. Immunoblot quantification of relative CCR9, CCR6, and CCR7 protein 
levels on membranes of receptor-expressing NIH-3T3 cells transduced with a control lentivirus (Con-
RNAi; 100%) or with lentiviral-mediated RNAi inhibition of CCR9 (CCR9-RNAi). Data represent 
mean ± S.D., n=4; *, p<0.0001. B. Immunoblot detection of CCR9 with affinity-purified anti-CCR9 
antibodies (IB: anti-CCR9) on membranes of circulating mononuclear cells (Mononucl. cells) isolated 
from APOE-deficient mice (APOE-/-) with lentiviral-mediated RNAi inhibition of CCR9 in 
hematopoietic progenitors (CCR9-RNAi) relative to APOE-deficient mice transplanted with cells 
transduced with a control lentivirus (Con-RNAi); n=5 mice/group. C. Immunoblot detection of CCR9 
(IB: anti-CCR9) on membranes of circulating mononuclear cells isolated from 28 week-old untreated 
APOE-deficient mice (Untreat., APOE-/-), captopril-treated APOE-deficient mice (Capto., APOE-/-), 
and untreated non-transgenic C57BL/6J control mice (Cont., APOE+/+); n=2 mice/group. B & C. 
Lower panels show immunoblots of β-actin demonstrating equal protein loading (IB: anti-actin). D. 
Quantification of relative aortic CCR9 protein levels of APOE-deficient mice (APOE-/-) with 
lentiviral-mediated RNAi inhibition of CCR9 in hematopoietic progenitors (CCR9-RNAi) relative to 
APOE-deficient mice transplanted with cells transduced with a control lentivirus (Con-RNAi; 100 %) 
by densitometric immunoblot scanning. As a control, aortic CCR9 protein levels were quantified of 
age-matched, untreated APOE-deficient mice (Untreated; 100 %), captopril-treated APOE-deficient 
mice (Captopril, 4 months of treatment), losartan-treated APOE-deficient mice (Losartan, 4 months of 
treatment), and non-transgenic C57BL/6J control mice (Control, APOE+/+). Data represent mean ± 
S.D., n=5 mice/group; *, p<0.001. E. Oil-red O staining of the aorta revealed a significantly decreased 
atherosclerotic plaque area upon lentiviral-mediated RNAi inhibition of CCR9 in hematopoietic 
progenitors (CCR9-RNAi) relative to APOE-deficient mice receiving transplantation of cells 
transduced with a control lentivirus (Con-RNAi). F. Quantification of atherosclerotic lesion area was 
performed by quantitative image analysis of the oil-red O stained lesion area of the aorta. Data are 
reported as the percent of the aortic surface area covered by lesions of APOE-deficient mice with 
lentiviral-mediated RNAi inhibition of CCR9 in hematopoietic progenitors (CCR9-RNAi), and 
APOE-deficient mice receiving transplantation of control lentivirus-transduced cells (Con-RNAi); *; 
p<0.001 (n=5). G. Body weight, systolic blood pressure, and total plasma cholesterol were not 
significantly different between 28 week-old APOE-deficient (APOE-/-) mice with lentiviral-mediated 
inhibition of CCR9 in hematopoietic progenitors (CCR9-RNAi), and APOE-deficient mice 
transplanted with cells transduced with a control lentivirus (Con-RNAi). Data represent mean ± S.D., 
n=5 mice/group. 
 
 Fig. 8. Infiltrates of CCR9-positive cells in atherosclerotic lesions of patients with coronary 
artery disease. A. Atherosclerotic lesions of human coronary artery biopsy specimens from patients 
undergoing coronary artery bypass surgery were identified by positive oil-red O staining of 
cryosections (left versus right panel). B. Coronary artery biopsy specimens with atherosclerotic 
lesions showed strong infiltration of CCR9 positive cells (left panel) whereas CCR9 was almost 
undetectable on vessel specimens without oil-red O-positive lesions (right panel). A & B, 
immunohistology data are representative of 6 different patients each (bar: 100 µm). C. The left panel 
shows immunoblot detection of CCR9 (IB: anti-CCR9) on membranes of coronary artery biopsy 
specimens with atherosclerotic lesions (Atheroscl. lesions; n=8) relative to control specimens without 
atherosclerotic lesions (Controls; n=7) obtained from patients undergoing coronary artery bypass 
surgery. As a control, pre-absorption of the antibodies by the immunizing antigen abolished the 
specific staining (lane P). The lower panel shows a control immunoblot detecting β-actin (IB: anti-
actin). The right panel represents an immunoblot detection of CCR9 with affinity-purified CCR9-
specific antibodies pre-absorbed to human proteins on membranes of HEK cells (HEK) over-
expressing CCR9 (lane 1; +) compared with mock-transfected cells (lane 2; -). 
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